Johnson & Johnson (JNJ) Wins First-Ever FDA Approval For Non-Chemo Treatment Of Lung Cancer

Hey everyone, Dylan Jovine here with Behind the Markets. It's Thursday, August 22nd, and today we’re diving into some big news from Johnson & Johnson. This week, J&J made headlines by winning FDA approval for RYBREVANT, the first chemotherapy-free treatment for non-small cell lung cancer in adults with the EGFR mutation. This is a huge step forward in the fight against cancer, moving away from the blunt force of chemotherapy to more precise, targeted treatments.
What’s exciting about RYBREVANT, especially when combined with LAZCLUZE, is its ability to act like a kill switch, shutting down the excessive cell division caused by the EGFR mutation. This is a first-line treatment, which means it has the potential to reach a large number of patients, offering hope where old-school chemo often falls short. With this approval, J&J is positioning itself at the forefront of a new era in cancer treatment.
As for J&J’s stock, it’s been stuck in a bit of a range lately, but with this new drug, I’m adding it to my watchlist. This development could be a game-changer, and I’ll be keeping a close eye on how things progress. Stay tuned for more updates, and have a great day!
✅ SUBSCRIBE TO THE CHANNEL 👇🏼👇🏼
/ @behindthemarkets
✅ VISIT OUR WEBSITE 👇🏼👇🏼
behindthemarke...